[Skip to Content]
[Skip to Content Landing]
Article
December 1992

Elevated Neopterin Levels in Guillain-Barré Syndrome: Further Evidence of Immune Activation

Author Affiliations

From the Department of Neurosciences, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark (Drs Bansil, Cook, and Rohowsky-Kochan); the Department of Veterans Affairs, John Cochran Medical Center, St Louis, Mo (Dr Mithen); St Louis University, School of Medicine (Dr Mithen); the Department of Neurology, Bombay (India) Hospital (Dr Singhal); and the Neurology Service, Veterans Affairs Medical Center, East Orange, NJ (Dr Cook).

Arch Neurol. 1992;49(12):1277-1280. doi:10.1001/archneur.1992.00530360079021
Abstract

• Neopterin is a by-product of guanosine triphosphate metabolism and is produced by macrophages in response to lymphocytic activation. We have studied serum neopterin levels in patients with Guillain-Barré syndrome to obtain further evidence of immune activation in this disease. Serum neopterin levels were significantly elevated in patients with Guillain-Barré syndrome compared with patients with other peripheral neuropathies and multiple sclerosis and with healthy control subjects. Serial analysis demonstrated that as neopterin levels fell, the clinical status of the patients with Guillain-Barré syndrome improved and soluble interleukin 2 receptor levels dropped. Thus, lymphocytic and macrophage activation may play a role in the pathogenesis of Guillain-Barré syndrome.

×